Financial & Business News

Wolfspeed (WOLF -16.35%) managed to close out the past week of trading with double-digit gains despite big sell-offs in the second half of the stretch. The company's share price climbed 12.3% from the previous week's market close.

VANCOUVER, BC , July 14, 2025 /PRNewswire/ -- Silver One Resources Inc. (TSXV: SVE) (OTCQX: SLVRF) (FSE: BRK1) ("Silver One" or the "Company") is pleased to announce that it has engaged Zonge International, Inc., to conduct a ground geophysical Induced Polarization (IP) and Magnetotelluric (MT) survey on its 100% owned Phoenix Silver project in Arizona. Both IP and MT are effective electrical geophysical methods useful to detect underground metallic minerals, especially disseminated sulfides, and structures that may be host to mineralization.

Analysts at J.P. Morgan are bearish on several high-profile stocks.

VANCOUVER, British Columbia, July 14, 2025 (GLOBE NEWSWIRE) -- VERSES AI Inc. (CBOE:VERS) (OTCQB:VRSSD) ("VERSES'' or the "Company”), a cognitive computing company specializing in next-generation intelligent software systems, is pleased to announce that it has closed its previously announced public offering of 1,007,764 units (the “Units”) of the Company at a price of C$9.50 (US$6.946) per Unit (the “Offering”). Pursuant to the Offering, the Company raised gross proceeds of approximately C$9,573,758 (US$7,000,331), before deducting commissions and estimated expenses incurred in connection with the Offering.

Enbridge remains a 'buy,' due to solid growth prospects, robust demand for energy, and a strong management growth plan, despite recent underperformance, versus the S&P 500. Recent financials show strong revenue and EBITDA growth, especially from Gas Distribution and Storage, boosted by acquisitions and rate increases. Management forecasts continued EBITDA and cash flow growth through 2026, supported by $28 billion in secured capital projects and substantial investment capacity.

"They don't need Nvidia's chips, certainly, or American tech stacks in order to build their military," Nvidia CEO Jensen Huang said in an interview with CNN aired Sunday. The comments came as Huang attempted to walk a tightrope between Beijing and the U.S. ahead of his second trip to China this year.

Nvidia (NVDA 0.53%) isn't just leading the artificial intelligence (AI) infrastructure boom: It is the boom. Its graphics processing units (GPUs) have become the backbone of AI data centers, while its CUDA software has helped create a huge moat around its business.

TBG is an actively managed ETF comprised of 30-40 U.S. companies selected for their dividend sustainability and ability to grow distributions over a 5-7 year market cycle. The fund's 0.59% expense ratio negatively impacts distributions, but its 2.40% trailing dividend yield is likely understated. This article explains why I expect it to gradually increase to the 3.50-3.60% range. TBG has solid quality and dividend growth features, though negative historical earnings growth rates have led to a high 66% payout ratio, 8% more than the four-year average.

Since the February update, an additional 5 patients have been dosed, resulting in 2 Complete Responses (CR) and 3 Partial Responses (PR) 75% Overall Response rate (ORR): 6 total CR and 3 PR in Phase 1b trial of azer-cel, an allogeneic off-the-shelf CD19 CAR T therapy in relapsed diffuse large B-cell lymphoma (DLBCL), an aggressive type of blood cancer First patient remains cancer free at 15 months and ongoing with additional patients having durable responses at 2, 5, and 11 months+ and durability data continuing to mature Patients in the trial have previously failed at least 3 lines of therapy with many patients failing 4-6 lines of therapy, including autologous CAR-T, reinforcing the potential of azer-cel in this high-unmet-need population Based on these positive results, Imugene expects to meet with the US FDA in Q4 2025 regarding a pivotal / registrational study for azer-cel Trial now open to enrol into CAR T naïve niche indications in other lymphomas Additional update expected in

TransMedics has rebounded from a sharp sell-off by consistently beating guidance and demonstrating strong execution, restoring investor confidence. I anticipate Q2 2025 will deliver another earnings beat, with flight activity data suggesting sales could surpass analyst estimates. The company is showing clear operating leverage, manageable debt, and is building a vertically integrated logistics network in a niche market.